Vanguard Group Inc. Boosts Stake in Dianthus Therapeutics, Inc. $DNTH

Vanguard Group Inc. raised its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 13.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,642,198 shares of the company’s stock after buying an additional 196,117 shares during the period. Vanguard Group Inc. owned about 5.10% of Dianthus Therapeutics worth $64,620,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of DNTH. Vestal Point Capital LP raised its holdings in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after buying an additional 1,499,931 shares during the period. Alliancebernstein L.P. boosted its holdings in Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock valued at $21,887,000 after acquiring an additional 149,200 shares during the period. Candriam S.C.A. grew its position in Dianthus Therapeutics by 25.3% in the 3rd quarter. Candriam S.C.A. now owns 301,428 shares of the company’s stock valued at $11,861,000 after acquiring an additional 60,852 shares during the last quarter. Sio Capital Management LLC grew its position in Dianthus Therapeutics by 101.8% in the 2nd quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock valued at $4,398,000 after acquiring an additional 119,073 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in Dianthus Therapeutics by 77.0% in the second quarter. Bank of America Corp DE now owns 165,125 shares of the company’s stock worth $3,076,000 after purchasing an additional 71,838 shares during the period. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Up 6.1%

Shares of NASDAQ DNTH opened at $65.20 on Friday. The business has a fifty day simple moving average of $48.42 and a two-hundred day simple moving average of $40.53. The firm has a market cap of $2.82 billion, a PE ratio of -18.74 and a beta of 1.56. Dianthus Therapeutics, Inc. has a twelve month low of $13.36 and a twelve month high of $65.50.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Jefferies Financial Group lifted their target price on Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. Truist Financial upped their price target on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. HC Wainwright lifted their price objective on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a report on Monday, November 10th. Finally, Wedbush boosted their price objective on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $67.63.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.